Nivolumab monotherapy in metastatic urothelial cancer (mUC): updated efficacy by subgroups and safety results from the CheckMate 032 study
© The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissionsoup.com.Background: Nivolumab has shown promising efficacy and acceptable safety in an open-label, multicenter phase...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
11 October 2016
|
| In: |
Annals of oncology
Year: 2016, Volume: 27 |
| ISSN: | 1569-8041 |
| DOI: | 10.1093/annonc/mdw373.12 |
| Online Access: | Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1093/annonc/mdw373.12 Verlag, kostenfrei, Volltext: https://academic.oup.com/annonc/article/27/suppl_6/784P/2799521 
|
| Author Notes: | J.E. Rosenberg, P. Bono, J. Kim, P. Spiliopoulou, E. Calvo, R. Pillai, P.A. Ott, F. de Braud, M. Morse, D. Le, D. Jaeger, E. Chan, C. Harbison, C.S. Lin, M. Tschaika, A. Azrilevich, P. Sharma |
| Summary: | © The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissionsoup.com.Background: Nivolumab has shown promising efficacy and acceptable safety in an open-label, multicenter phase I/II study in patients (pts) with mUC after ≥1 prior platinum-based therapy (NCT01928394). Here we report updated efficacy and safety results for the overall population based on additional follow-up and outcomes by differing levels of PD-L1 expression.Methods: Pts with mUC, unselected by PD-L1 expression status, received nivolumab 3 mg/kg IV every 2 wk until progression or discontinuation. Pts who met protocol criteria could continue treatment beyond progression and cross over to nivolumab + ipilimumab. Tumor PD-L1 membrane expression was assessed with Dako PD-L1 immunohistochemical staining. Primary endpoint: objective response rate (ORR; RECIST 1.1); other endpoints: safety, progression-free survival (PFS), overall survival (OS), and duration of response.Results: Of 78... |
|---|---|
| Item Description: | Gesehen am 10.11.2017 |
| Physical Description: | Online Resource |
| ISSN: | 1569-8041 |
| DOI: | 10.1093/annonc/mdw373.12 |